Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. On the estimation of average treatment effects with right-censored time to event outcome and competing risks

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Covariate-adjusted measures of discrimination for survival data

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor based approach

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Reward processing in major depressive disorder and prediction of treatment response - Neuropharm study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Net benefit in the presence of correlated prioritized outcomes using generalized pairwise comparisons: A simulation study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Eva Cantagallo
  • Mickaël De Backer
  • Michal Kicinski
  • Brice Ozenne
  • Laurence Collette
  • Catherine Legrand
  • Marc Buyse
  • Julien Péron
View graph of relations

In survival analysis with competing risks, the treatment effect is typically expressed using cause-specific or subdistribution hazard ratios, both relying on proportional hazards assumptions. This paper proposes a nonparametric approach to analyze competing risks data based on generalized pairwise comparisons (GPC). GPC estimate the net benefit, defined as the probability that a patient from the treatment group has a better outcome than a patient from the control group minus the probability of the opposite situation, by comparing all pairs of patients taking one patient from each group. GPC allow using clinically relevant thresholds and simultaneously analyzing multiple prioritized endpoints. We show that under proportional subdistribution hazards, the net benefit for competing risks settings can be expressed as a decreasing function of the subdistribution hazard ratio, taking a value 0 when the latter equals 1. We propose four net benefit estimators dealing differently with censoring. Among them, the Péron estimator uses the Aalen-Johansen estimator of the cumulative incidence functions to classify the pairs for which the patient with the best outcome could not be determined due to censoring. We use simulations to study the bias of these estimators and the size and power of the tests based on the net benefit. The Péron estimator was approximately unbiased when the sample size was large and the censoring distribution's support sufficiently wide. With one endpoint, our approach showed a comparable power to a proportional subdistribution hazards model even under proportional subdistribution hazards. An application of the methodology in oncology is provided.

Original languageEnglish
JournalBiometrical journal. Biometrische Zeitschrift
Volume63
Issue number2
Pages (from-to)272-288
Number of pages17
ISSN0323-3847
DOIs
Publication statusPublished - Feb 2021

    Research areas

  • clinical trial, competing risks, generalized pairwise comparisons, multicriteria analysis, survival analysis

ID: 65896592